tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cautious Outlook on Zentalis Pharmaceuticals Amid Strategic Focus and Financial Management
PremiumRatingsCautious Outlook on Zentalis Pharmaceuticals Amid Strategic Focus and Financial Management
2M ago
Zentalis Pharmaceuticals: Strategic Advancements and Promising Clinical Outcomes Justify Buy Rating
Premium
Ratings
Zentalis Pharmaceuticals: Strategic Advancements and Promising Clinical Outcomes Justify Buy Rating
2M ago
Zentalis Pharmaceuticals Reports Q1 2025 Financial Results
Premium
Company Announcements
Zentalis Pharmaceuticals Reports Q1 2025 Financial Results
3M ago
Zentalis announces first patient dosed in DENALI Part 2 trial of azenosertib
PremiumThe FlyZentalis announces first patient dosed in DENALI Part 2 trial of azenosertib
3M ago
Zentalis Highlights Azenosertib Findings at 2025 AACR
Premium
Company Announcements
Zentalis Highlights Azenosertib Findings at 2025 AACR
3M ago
Promising Potential and Strategic Positioning Justify Buy Rating for Zentalis Pharmaceuticals
Premium
Ratings
Promising Potential and Strategic Positioning Justify Buy Rating for Zentalis Pharmaceuticals
4M ago
Zentalis files $250M mixed securities shelf
PremiumThe FlyZentalis files $250M mixed securities shelf
4M ago
Zentalis Highlights Promising Azenosertib Data at SGO 2025
Premium
Company Announcements
Zentalis Highlights Promising Azenosertib Data at SGO 2025
5M ago
Positive Buy Rating for Zentalis Pharmaceuticals Driven by Promising Efficacy and Safety of Azenosertib in PROC Treatment
Premium
Ratings
Positive Buy Rating for Zentalis Pharmaceuticals Driven by Promising Efficacy and Safety of Azenosertib in PROC Treatment
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100